Spoken Alpha
ArriVent BioPharma, Inc.
ArriVent BioPharma develops cancer medicines, with a focus on non-small cell lung cancer. The company's lead candidate, firmonertinib, is an oral drug targeting specific EGFR mutations, currently in Phase 3 trials for patients with uncommon mutations (exon 20 insertions and PACC mutations) that lack effective treatment options.
ArriVent BioPharma, Inc is a Healthcare company operating in Biotechnology with a $1.42B market cap.
AVBP missed consensus EPS by 0.1% in Q3 FY2026, reported Aug 11, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add AVBP, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AVBP.
$ curl https://api.spokenalpha.com/v1/companies/AVBPFAQ
Spoken Alpha indexes AVBP's earnings call transcripts at https://spokenalpha.com/companies/AVBP. Each call links to attributed speakers and parsed analyst Q&A.
ArriVent BioPharma, Inc. (AVBP) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-08-11 | $-1.05 | $-0.98 | -7.1% | $0 | — | — | EODHD |
| Q2 FY2026 | 2026-05-10 | $-0.96 | $-0.89 | -7.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-03-25 | $-0.78 | $-0.82 | +4.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-11-09 | $-0.83 | $-0.78 | -6.4% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-08-10 | $-0.90 | $-0.71 | -26.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-05-11 | $-1.90 | $-0.69 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-03-02 | $-0.60 | $-0.46 | -30.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-11-13 | $-0.61 | $-1.07 | +43.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-08-13 | $-0.65 | $-0.59 | -10.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-05-07 | $-0.70 | $-1.30 | +46.2% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-03-27 | $-0.70 | $-1.10 | +36.4% | $0 | — | — | EODHD |
Source: EODHD. AVBP reported actuals as published; sparse fields render as —.